Newomics Inc. is dedicated to creating and commercializing innovative (New) and also integrative (Omics) platforms and solutions for precision medicine. Their initial M3 emitter product line enables unprecedented gains in sensitivity, throughput, and also robustness for liquid chromatography – mass spectrometry (LC-MS). The multinozzle emitter array (MEA) technology, invented at the Lawrence Berkeley National Laboratory, won the 2012 R&D 100 award.
They apply their technology in order to develop multiomics diagnostic assays for diabetes, Alzheimer’s, and other diseases. Newomics is also developing a microfluidic device to sort, count, and remove cells based on size from blood (the Senescence Chip). The impact of their publications led to a ranking of #71 among the top 100 corporations in the US that dominated research in the natural sciences in 2018.
In order to find more information on the company, please visit their website: here.